Cargando…
Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes
BACKGROUND: It is unclear if direct-acting oral anticoagulants (DOACs) use before hospitalization due to COVID-19 diagnosis would potentially impact the severity and clinical outcomes thereafter. We compared 30-day hospitalization/re-hospitalization and clinical outcomes between patients on chronic...
Autores principales: | Rivera-Caravaca, José Miguel, Buckley, Benjamin J.R., Harrison, Stephanie L., Fazio-Eynullayeva, Elnara, Underhill, Paula, Marín, Francisco, Lip, Gregory Y.H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236305/ https://www.ncbi.nlm.nih.gov/pubmed/34218058 http://dx.doi.org/10.1016/j.thromres.2021.06.014 |
Ejemplares similares
-
Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases
por: Rivera-Caravaca, José Miguel, et al.
Publicado: (2021) -
End-Stage renal disease and 30-day mortality for adults with and without COVID-19
por: Harrison, Stephanie L., et al.
Publicado: (2021) -
Atrial fibrillation and the risk of 30‐day incident thromboembolic events, and mortality in adults ≥ 50 years with COVID‐19
por: Harrison, Stephanie L., et al.
Publicado: (2020) -
Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2022) -
Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real‐World Data
por: Buckley, Benjamin J. R., et al.
Publicado: (2021)